Pediatric papillary thyroid cancer: current management challenges

References

• RivkeesSAMazzaferriELVerburgFAThe treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapyEndocr Rev201132679882621880704
   PubMed Web of Science ®Google Scholar
• HoganARZhugeYPerezEAKoniarisLGLewJISolaJEPediatric thyroid carcinoma: incidence and outcomes in 1753 patientsJ Surg Res2009156116717219631341
   PubMedGoogle Scholar
• DemidchikYESaenkoVAYamashitaSChildhood thyroid cancer in Belarus, Russia, and Ukraine after Chernobyl and at presentArq Bras Endocrinol Metabol200751574876217891238
   PubMedGoogle Scholar
• FrancisGLWaguespackSGBauerAJAmerican Thyroid Association Guidelines Task ForceManagement guidelines for children with thyroid nodules and differentiated thyroid cancerThyroid201525771675925900731
   PubMed Web of Science ®Google Scholar
• HaugenBRAlexanderEKBibleKC2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancerThyroid2016261113326462967
   PubMed Web of Science ®Google Scholar
• ClementSCKremerLCLinksTPIs outcome of differentiated thyroid carcinoma influenced by tumor stage at diagnosis?Cancer Treat Rev201541191625544598
   PubMed Web of Science ®Google Scholar
• VerburgFAMaderULusterMReinersCPrimary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinomaClin Endocrinol (Oxf)200971229129719067727
   PubMedGoogle Scholar
• MachensAHolzhusenHJDralleHThe prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. A comparative analysisCancer2005103112269227315856429
   PubMed Web of Science ®Google Scholar
• JarzabBHandkiewiczJDWlochJMultivariate analysis of prognostic factors for differentiated thyroid carcinoma in childrenEur J Nucl Med200027783384110952495
   PubMedGoogle Scholar
• MihailovicJNikoleticKSrbovanDRecurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomesJ Nucl Med201455571071724722527
   PubMedGoogle Scholar
• Handkiewicz-JunakDWlochJRoskoszJTotal thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancerJ Nucl Med200748687988817536106
   PubMedGoogle Scholar
• HayIDGonzalez-LosadaTReinaldaMSHonetschlagerJARichardsMLThompsonGBLong-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008World J Surg20103461192120220087589
   PubMedGoogle Scholar
• DralleHSekullaCHaertingJRisk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgerySurgery200413661310132215657592
   PubMed Web of Science ®Google Scholar
• MusholtTJClericiTDralleHInterdisciplinary task force guidelines of the German Association of Endocrine SurgeonsGerman association of endocrine surgeons practice guidelines for the surgical treatment of benign thyroid diseaseLangenbecks Arch Surg2011396563964921424798
   PubMedGoogle Scholar
• ThomuschOMachensASekullaCUkkatJBrauckhoffMDralleHThe impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patientsSurgery2003133218018512605179
   PubMedGoogle Scholar
• ReinersCBikoJHaenscheidHTwenty-five years after chernobyl: outcome of radioiodine treatment in children and adolescents with very-high-risk radiation-induced differentiated thyroid carcinomaJ Clin Endocrinol Metab20139873039304823616148
   PubMedGoogle Scholar
• VerburgFAMaderULusterMHanscheidHReinersCDeterminants of successful ablation and complete remission after total thyroidectomy and 131I therapy of paediatric differentiated thyroid cancerEur J Nucl Med Mol Imaging20154291390139826070546
   PubMedGoogle Scholar
• HanscheidHLassmannMLusterMIodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawalJ Nucl Med200647464865416595499
   PubMedGoogle Scholar
• SamuelAMRajashekharraoBShahDHPulmonary metastases in children and adolescents with well-differentiated thyroid cancerJ Nucl Med1998399153115369744337
   PubMedGoogle Scholar
• Klubo-GwiezdzinskaJVan NostrandDAtkinsFEfficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancerJ Clin Endocrinol Metab201196103217322521849530
   PubMedGoogle Scholar
• BenuaRSCicaleNRSonenbergMRawsonRWThe relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancerAm J Roentgenol Radium Ther Nucl Med196287171182
   PubMedGoogle Scholar
• BenuaRSLeeperRDA method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131Medeiros-NetoGGaitanGFrontiers In ThyroidologyNew York, NYPlenum Medical Book Co198613171321
   Google Scholar
• VerburgFAHanscheidHBikoJDosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experienceEur J Nucl Med Mol Imaging201037589690320033685
   PubMed Web of Science ®Google Scholar
• MaxonHRThomasSRHertzbergVSRelation between effective radiation dose and outcome of radioiodine therapy for thyroid cancerN Engl J Med1983309169379416621620
   PubMedGoogle Scholar
• MaxonHR3rdEnglaroEEThomasSRRadioiodine-131 therapy for well-differentiated thyroid cancer – a quantitative radiation dosimetric approach: outcome and validation in 85 patientsJ Nucl Med1992336113211361597728
   PubMed Web of Science ®Google Scholar
• DornRKoppJVogtHHeidenreichPCarrollRGGulecSADosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approachJ Nucl Med200344345145612621014
   PubMed Web of Science ®Google Scholar
• ChiesaCCastellaniMRVellaniCIndividualized dosimetry in the management of metastatic differentiated thyroid cancerQ J Nucl Med Mol Imaging200953554656119910908
   PubMedGoogle Scholar
• FluxGDHaqMChittendenSJA dose-effect correlation for radioiodine ablation in differentiated thyroid cancerEur J Nucl Med Mol Imaging201037227027519760413
   PubMedGoogle Scholar
• LassmannMHaenscheidHChiesaCHindorfCFluxGLusterMEANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapyEur J Nucl Med Mol Imaging20083571405141218491092
   PubMed Web of Science ®Google Scholar
• LassmannMHanscheidHVerburgFALusterMThe use of dosimetry in the treatment of differentiated thyroid cancerQ J Nucl Med Mol Imaging201155210711521386785
   PubMedGoogle Scholar
• LassmannMLusterMHanscheidHReinersCImpact of 131I diagnostic activities on the biokinetics of thyroid remnantsJ Nucl Med200445461962515073258
   PubMedGoogle Scholar
• VerburgFAVerkooijenRBStokkelMPvan IsseltJWThe success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131INuklearmedizin200948413814219384451
   PubMedGoogle Scholar
• TuttleRMLeboeufRRobbinsRJEmpiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancerJ Nucl Med200647101587159117015892
   PubMed Web of Science ®Google Scholar
• KulkarniKVan NostrandDAtkinsFAikenMBurmanKWartofskyLThe relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancerThyroid200616101019102317042688
   PubMedGoogle Scholar
• ICRPBasic Anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89Ann ICRP2002323–4526514506981
   PubMedGoogle Scholar
• ICRPRadiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP publication 53. ICRP publication 106. Approved by the Commission in October 2007Ann ICRP2008381–2119719154964
   PubMedGoogle Scholar
• SgourosGSongHLadensonPWWahlRLLung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi ruleJ Nucl Med200647121977198417138740
   PubMedGoogle Scholar
• HobbsRFWahlRLLodgeMA124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparisonJ Nucl Med200950111844184719837771
   PubMedGoogle Scholar
• SongHHeBPrideauxALung dosimetry for radioiodine treatment planning in the case of diffuse lung metastasesJ Nucl Med200647121985199417138741
   PubMedGoogle Scholar
• VerburgFAReinersCHanscheidHApproach to the patient: role of dosimetric RAI Rx in children with DTCJ Clin Endocrinol Metab201398103912391924098014
   PubMedGoogle Scholar
• LusterMClarkeSEDietleinMEuropean Association of Nuclear Medicine (EANM)Guidelines for radioiodine therapy of differentiated thyroid cancerEur J Nucl Med Mol Imaging200835101941195918670773
   PubMed Web of Science ®Google Scholar
• PaciniFSchlumbergerMDralleHEliseiRSmitJWWiersingaWEuropean Thyroid Cancer TaskforceEuropean consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumEur J Endocrinol2006154678780316728537
   PubMed Web of Science ®Google Scholar
• CooperDSDohertyGMHaugenBRRevised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid200919111167121419860577
   PubMed Web of Science ®Google Scholar
• VrachimisARiemannBMaderUReinersCVerburgFAEndogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortalityEur J Nucl Med Mol Imaging Epub20151023
   Google Scholar
• LusterMFelbingerRDietleinMReinersCThyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administrationThyroid200515101147115516279848
   PubMed Web of Science ®Google Scholar
• DowKHFerrellBRAnelloCQuality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapyThyroid1997746136199292951
   PubMedGoogle Scholar
• SchroederPRHaugenBRPaciniFA comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawalJ Clin Endocrinol Metab200691387888416394083
   PubMed Web of Science ®Google Scholar
• RosarioPWBorgesMAPurischSPreparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicityJ Nucl Med200849111776178218927337
   PubMedGoogle Scholar
• FrigoADardanoADaneseEChromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawalJ Clin Endocrinol Metab20099493472347619509107
   PubMedGoogle Scholar
• HaugenBRPaciniFReinersCA comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancerJ Clin Endocrinol Metab199984113877388510566623
   PubMedGoogle Scholar
• PaciniFLadensonPWSchlumbergerMRadioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled studyJ Clin Endocrinol Metab200691392693216384850
   PubMed Web of Science ®Google Scholar
• SchlumbergerMCatargiBBorgetIStrategies of radioiodine ablation in patients with low-risk thyroid cancerN Engl J Med2012366181663167322551127
   PubMed Web of Science ®Google Scholar
• MallickUHarmerCYapBAblation with low-dose radioiodine and thyrotropin alfa in thyroid cancerN Engl J Med2012366181674168522551128
   PubMed Web of Science ®Google Scholar
• GoslingsBMProceedings: effect of a low iodine diet on 131-I therapy in follicular thyroid carcinomataJ Endocrinol197564330P
   PubMedGoogle Scholar
• MaxonHRThomasSRBoehringerALow iodine diet in I-131 ablation of thyroid remnantsClin Nucl Med1983831231266851357
   PubMedGoogle Scholar
• ParkJTHennesseyJVTwo-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxineThyroid200414576315009915
   PubMedGoogle Scholar
• PluijmenMJEustatia-RuttenCGoslingsBMEffects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinomaClin Endocrinol (Oxf)200358442843512641625
   PubMedGoogle Scholar
• SonenbergMLow-iodine diet in the treatment of differentiated thyroid cancer with radioactive iodineEndocrine200217214114312041916
   PubMedGoogle Scholar
• BohuslavizkiKHKlutmannSJenickeLSalivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trialCancer Biother Radiopharm199914533734710850318
   PubMed Web of Science ®Google Scholar
• KimSJChoiHYKimIJLimited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scanThyroid200818332533118341378
   PubMedGoogle Scholar
• JentzenWBalschuweitDSchmitzJThe influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imagingEur J Nucl Med Mol Imaging201037122298230620625723
   PubMedGoogle Scholar
• NakadaKIshibashiTTakeiTDoes lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?J Nucl Med200546226126615695785
   PubMedGoogle Scholar
• WiersingaWMDuntasLFadeyevVNygaardBVanderpumpMP2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidismEur Thyroid J201212557124782999
   PubMedGoogle Scholar
• McLeodDSCooperDSLadensonPWThe National Thyroid Cancer Treatment Cooperative Study Group SIPrognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosisThyroid2014241354223731273
   PubMed Web of Science ®Google Scholar
• SmitJWEustatia-RuttenCFCorssmitEPReversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled studyJ Clin Endocrinol Metab200590116041604716131580
   PubMed Web of Science ®Google Scholar
• SelmerCOlesenJBHansenMLThe spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort studyBMJ2012345e789523186910
   PubMed Web of Science ®Google Scholar
• ChakerLHeeringaJDehghanANormal thyroid function and the risk of atrial fibrillation: the rotterdam studyJ Clin Endocrinol Metab2015100103718372426262438
   PubMed Web of Science ®Google Scholar
• HovensGCStokkelMPKievitJAssociations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancerJ Clin Endocrinol Metab20079272610261517426094
   PubMed Web of Science ®Google Scholar
• CooperDSSpeckerBHoMThyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National thyroid cancer treatment cooperative registryThyroid1998897377449777742
   PubMed Web of Science ®Google Scholar
• DiesslSHolzbergerBMaderUImpact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinomaClin Endocrinol (Oxf)201276458659222059804
   PubMed Web of Science ®Google Scholar
• BikoJReinersCKreisslMCVerburgFADemidchikYDrozdVFavourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-upEur J Nucl Med Mol Imaging201138465165521113590
   PubMedGoogle Scholar
• ClementSCPeetersRPRonckersCMIntermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma – a systematic reviewCancer Treat Rev2015411092593426421813
   PubMed Web of Science ®Google Scholar
• HayIDBergstralhEJGrantCSImpact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989Surgery199912661173118110598204
   PubMedGoogle Scholar
• SawkaAMThabaneLParleaLSecond primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysisThyroid200919545145719281429
   PubMed Web of Science ®Google Scholar
• VerkooijenRBSmitJWRomijnJAStokkelMPThe incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancerEur J Endocrinol2006155680180617132748
   PubMedGoogle Scholar
• AlexanderCBaderJBSchaeferAFinkeCKirschCMIntermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinomaJ Nucl Med1998399155115549744341
   PubMed Web of Science ®Google Scholar
• SolansRBoschJAGalofrePSalivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapyJ Nucl Med200142573874311337569
   PubMed Web of Science ®Google Scholar
• Van NostrandDSialoadenitis secondary to 131I therapy for well-differentiated thyroid cancerOral Dis201117215416121029259
   PubMedGoogle Scholar
• DottoriniMEVignatiAMazzucchelliLLomuscioGColomboLDifferentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patientsJ Nucl Med19973856696759170425
   PubMedGoogle Scholar
• SeidlinSMSiegalEYalowAAMelamedSAcute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinomaScience1956123320180080113324088
   PubMedGoogle Scholar
• SubramanianSGoldsteinDPParleaLSecond primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysisThyroid200717121277128818020916
   PubMedGoogle Scholar
• IyerNGMorrisLGTuttleRMShahaARGanlyIRising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapyCancer2011117194439444621432843
   PubMed Web of Science ®Google Scholar
• HanscheidHLassmannMLusterMKloosRTReinersCBlood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinomaEndocr Relat Cancer20091641283128919628649
   PubMedGoogle Scholar
• VerburgFALassmannMMaderULusterMReinersCHanscheidHThe absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patientsEur J Nucl Med Mol Imaging201138467368021210115
   PubMedGoogle Scholar
• HanscheidHVerburgFABikoJSuccess of the postoperative (131)I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin levelEur J Nucl Med Mol Imaging20113871296130221461735
   PubMedGoogle Scholar
• DuranteCHaddyNBaudinELeboulleuxSLong-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapyJ Clin Endocrinol Metab20069182892289916684830
   PubMed Web of Science ®Google Scholar
• VerburgFAMaderUKruitwagenCLLusterMReinersCA comparison of prognostic classification systems for differentiated thyroid carcinomaClin Endocrinol (Oxf)201072683083819863574
   PubMedGoogle Scholar
• BrierleyJDPanzarellaTTsangRWGospodarowiczMKO’SullivanBA comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an exampleCancer19977912241424239191532
   PubMedGoogle Scholar
• TuttleRMTalaHShahJEstimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new american thyroid association staging systemThyroid201020121341134921034228
   PubMed Web of Science ®Google Scholar
• BlumMTiuSChuMGoelSFriedmanKI-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patientsThyroid201121111235124722007920
   PubMedGoogle Scholar
• VerburgFAStokkelMPDurenCNo survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancerEur J Nucl Med Mol Imaging201037227628320091165
   PubMedGoogle Scholar